CD8A and B-cell chronic lymphocytic leukemia: Immunomodulatory analyses did not solidify the impact of elevated BAs in CLL; however, BAs found to be differentially abundant in CLL patients displayed distinct immunomodulatory action (i.e., impaired CD8+ T-cell proliferation (Figure 4B) compared to less differential BAs.